These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 36032811)
21. Uterine mesenchymal tumors harboring Kyi C; Friedman CF; Mueller JJ; Benayed R; Ladanyi M; Arcila M; Yang SR; Hensley ML; Chiang S Gynecol Oncol Rep; 2021 Aug; 37():100852. PubMed ID: 34522753 [TBL] [Abstract][Full Text] [Related]
22. Case Report: Early Distant Metastatic Inflammatory Myofibroblastic Tumor Harboring Han Q; He X; Cui L; Qiu Y; Li Y; Chen H; Zhang H Front Med (Lausanne); 2022; 9():826705. PubMed ID: 35280868 [TBL] [Abstract][Full Text] [Related]
23. Uterine Inflammatory Myofibroblastic Tumors Frequently Harbor ALK Fusions With IGFBP5 and THBS1. Haimes JD; Stewart CJR; Kudlow BA; Culver BP; Meng B; Koay E; Whitehouse A; Cope N; Lee JC; Ng T; McCluggage WG; Lee CH Am J Surg Pathol; 2017 Jun; 41(6):773-780. PubMed ID: 28490045 [TBL] [Abstract][Full Text] [Related]
24. Uterine inflammatory myofibroblastic tumors in pregnant women with and without involvement of the placenta: a study of 6 cases with identification of a novel TIMP3-RET fusion. Cheek EH; Fadra N; Jackson RA; Davila JI; Sukov WR; Uckerman MT; Clayton A; Keeney GL; Halling KC; Torres-Mora J; Schoolmeester JK Hum Pathol; 2020 Mar; 97():29-39. PubMed ID: 31917155 [TBL] [Abstract][Full Text] [Related]
25. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review. Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785 [TBL] [Abstract][Full Text] [Related]
26. Impact of ALK Inhibitors in Patients With Takeyasu Y; Okuma HS; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Shimoi T; Noguchi E; Arakawa A; Mori T; Sunami K; Kubo T; Kohno T; Akihiko Y; Yamamoto N; Yonemori K JCO Precis Oncol; 2021; 5():. PubMed ID: 34036223 [TBL] [Abstract][Full Text] [Related]
27. Update of Diagnosis and Targeted Therapy for ALK Wang QA; Chen HW; Wu RC; Wu CE Curr Treat Options Oncol; 2023 Dec; 24(12):1683-1702. PubMed ID: 37938503 [TBL] [Abstract][Full Text] [Related]
28. ALK-Rearranged NSCLC With Concomitant HER2-Mutant Breast Cancer Patient Treated With Alectinib, Trastuzumab, and Pertuzumab: A Case Report. Takayasu H; Kata Y; Otsu Y; Inoue S; Kaneko T Cureus; 2023 Mar; 15(3):e36711. PubMed ID: 37113357 [TBL] [Abstract][Full Text] [Related]
29. Inflammatory myofibroblastic tumor of the urinary bladder with FN1‑ALK gene fusion: A case report. Son SM; Woo CG; Lee OJ; Kim YJ; Lee HC Oncol Lett; 2023 Jun; 25(6):227. PubMed ID: 37153035 [TBL] [Abstract][Full Text] [Related]
30. Recurrent Inflammatory Myofibroblastic Tumor of Larynx Harboring a Novel THBS1::ALK Fusion. Ajmal N; Gargano SM; Gosavi U; Tuluc M Int J Genomics; 2024; 2024():4937501. PubMed ID: 39171208 [TBL] [Abstract][Full Text] [Related]
31. Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report. Takahashi A; Kurosawa M; Uemura M; Kitazawa J; Hayashi Y J Int Med Res; 2018 Aug; 46(8):3498-3503. PubMed ID: 29900760 [TBL] [Abstract][Full Text] [Related]
32. Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene. Saiki M; Ohyanagi F; Ariyasu R; Koyama J; Sonoda T; Nishikawa S; Kitazono S; Yanagitani N; Horiike A; Ninomiya H; Ishikawa Y; Nishio M Jpn J Clin Oncol; 2017 Dec; 47(12):1189-1192. PubMed ID: 28977547 [TBL] [Abstract][Full Text] [Related]
33. Pregnancy-associated Inflammatory Myofibroblastic Tumors of the Uterus Are Clinically Distinct and Highly Enriched for TIMP3-ALK and THBS1-ALK Fusions. Devereaux KA; Fitzpatrick MB; Hartinger S; Jones C; Kunder CA; Longacre TA Am J Surg Pathol; 2020 Jul; 44(7):970-981. PubMed ID: 32271187 [TBL] [Abstract][Full Text] [Related]
34. Exceptional response to alectinib for duodenal carcinoma with Isaka Y; Sasaki A; Saito A; Motomura Y; Ando Y; Nakamura Y Front Oncol; 2022; 12():1064944. PubMed ID: 36713517 [TBL] [Abstract][Full Text] [Related]
35. Uterine inflammatory myofibroblastic tumor. Karpathiou G; Devouassoux-Shisheboran M; Stolnicu S; Chauleur C; Péoc'h M Pathol Res Pract; 2023 Feb; 242():154335. PubMed ID: 36706588 [TBL] [Abstract][Full Text] [Related]
36. ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract. Fuehrer NE; Keeney GL; Ketterling RP; Knudson RA; Bell DA Arch Pathol Lab Med; 2012 Jun; 136(6):623-6. PubMed ID: 22646268 [TBL] [Abstract][Full Text] [Related]
37. ALK-rearranged Tumors Are Highly Enriched in the STUMP Subcategory of Uterine Tumors. Devereaux KA; Kunder CA; Longacre TA Am J Surg Pathol; 2019 Jan; 43(1):64-74. PubMed ID: 29794871 [TBL] [Abstract][Full Text] [Related]
39. Analysis of the resistance profile of real-world alectinib first-line therapy in patients with Xie Y; Zhang Y; Wu Y; Xie X; Lin X; Tang Q; Zhou C; Xie Z J Thorac Dis; 2024 Jun; 16(6):3854-3863. PubMed ID: 38983150 [TBL] [Abstract][Full Text] [Related]
40. New Perspectives in the Treatment of Inflammatory Myofibroblastic Tumor with ALK Translocation: Case Report. Benedetti Pedroza J; Carrasco García I; Martínez Bernal G; Miras Rodriguez I Case Rep Oncol; 2024; 17(1):763-772. PubMed ID: 39144250 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]